Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 0812 • ACR Convergence 2021
Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
Mary Lucy Marques¹, Alessia Alunno², Louise Falzon³, Annelies Boonen⁴ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University of Perugia, Perugia, Italy, ³Center for Personalized Health, Northwell Health, New York City, NY, ⁴Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands
Background/Purpose: Treatment of early RA with DMARDs is associated with particularly effective responses, resulting in sustained beneficial outcomes, including clinical and radiographic remission and optimal…
Abstract Number: L07 • 2019 ACR/ARP Annual Meeting
A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis
Liam O'Neil¹, Victor Spicer ¹, Irene Smolik ¹, Xiaobo Meng ¹, John Wilkins ¹ and Hani El-Gabalawy ², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are currently the primary biomarker for identifying individuals at increased risk for future RA development. However, we have recently shown…
Abstract Number: 485 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis
Candice Low¹, Richard Conway ², Francis Young ¹, Eamonn Molloy ³, Anne Barbara Mongey ³, Gerry Wilson ³, Ursula Fearon ⁴ and Douglas Veale ⁵, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Blackrock Clinic, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁵EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). It is a precursor to…
Abstract Number: 2324 • 2019 ACR/ARP Annual Meeting
Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Francisco Guiñazú¹, Carla Gobbi ², Paula Alba ¹, Carla Maldini ³, Carla Alonso ¹, Alejandro Albiero ¹, Eduardo Albiero ¹, Viviana Neme ⁴, Marcela Demarchi ⁴ and Marcelo Yorio ³, ¹UNIDAD DE REUMATOLOGÍA, CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ²CÁTEDRA DE CLÍNICA MÉDICA I, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ³CÁTEDRA DE SEMIOLOGÍA, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ⁴SERVICIO DE BIOQUÍMICA. HOSPITAL CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina
Background/Purpose: The Metabolic Syndrome (MetS) is an independent factor of cardiovascular morbidity and mortality and most studies show that its prevalence is higher in established…
Abstract Number: 486 • 2019 ACR/ARP Annual Meeting
Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis
Candice Low¹, Richard Conway ², Francis Young ¹, Eamonn Molloy ³, Anne Barbara Mongey ³, Gerry Wilson ³, Ursula Fearon ⁴ and Douglas Veale ⁵, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Blackrock Clinic, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁵EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). In some individuals it is…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Jessica Torres Chichande¹, Santiago Ruta ², Einer Sanchez Prado ³, Alvaro Ruta ¹, Sebastian Magri ¹, Facundo Salvatori ¹ and Rodrigo Garcia Salinas ¹, ¹Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ²Rheumatology Department, Hospital San Martín de La Plata and Rheumatology Unit, Hospital Italiano de La Plata, Argentina., La Plata, Argentina, ³Hospital Italiano de La Plata, La Plata
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…
Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Rebecca Overbury¹, Shaobo Pei ², Gopi Penmetsa ³, Brian Sauer ², Vikas Patil ², Jodi Walker ⁴, Jerry Clewell ⁴, Kevin Douglas ⁴, Daniel Clegg ⁵, Grant Cannon ⁶, Ahmad Halwani ⁷ and Jessica Walsh ⁸, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴AbbVie Inc., Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁷Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…
Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Meliha Kapetanovic¹, Maria Andersson ², Alan Friedman ³, Tim Shaw ³, Yanna Song ⁴, Daniel Aletaha ⁵, Maya H. Buch ⁶, Ulf Müller-Ladner ⁷ and Janet Pope ⁸, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ²Abbvie AB, Solna, Sweden, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Medical University of Vienna, Vienna, Austria, ⁶University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁷Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁸Western University, London, ON, Canada
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 107 • 2019 ACR/ARP Annual Meeting
Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
William Murray-Brown¹, Yanxia Guo ², Mihir Wechalekar ¹, Helen Weedon ¹, Malcolm Smith ¹, Susanna Proudman ³, Navin Rao ⁴, Sunil Nagpal ⁴ and Mihir Wechalekar ¹, ¹Flinders University, Adelaide, Australia, ²Janssen Research, Spring House, ³Adelaide University, Adelaide, Australia, ⁴Janssen R&D, Spring House, PA
Background/Purpose: Programmed cell death protein 1 (PD-1) expressing T-cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis (RA). In secondary…
Abstract Number: 1182 • 2019 ACR/ARP Annual Meeting
Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Yogan Kisten¹, Adrian Levitsky ¹, Hamed Rezaei ¹, Aase Hensvold ², Per Larsson ³, Erik af Klint ¹, Ronald van Vollenhoven ⁴ and Anca Catrina ⁵, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁴Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ⁵Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Among the arsenal of available techniques for arthritis prediction and diagnosis, fluorescence optical imaging (FOI) has shown to be useful in detecting clinically manifest…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].